Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.45 |
| ▸ | TK2 | O00142 | 3/20 | 0.45 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723505 | 0.92 | TYMP (0.43) | TYMPTK2RNASE1 | |
| SCHEMBL25403441 | 0.91 | TYMP (0.44) | TYMPTK2RNASE1ALDH1A1LMNA | |
| SCHEMBL25400439 | 0.91 | TYMP (0.44) | TYMPTK2RNASE1ALDH1A1LMNA | |
| SCHEMBL781655 | 0.86 | SLC28A1 (0.47) | TYMPTK2 | |
| SCHEMBL781654 | 0.86 | SLC28A1 (0.47) | TYMPTK2 | |
| SCHEMBL7702799 | 0.84 | TYMP (0.54) | TYMPTK2 | |
| SCHEMBL22984025 | 0.84 | TYMP (0.54) | TYMPTK2 | |
| SCHEMBL7702801 | 0.84 | TYMP (0.54) | TYMPTK2 | |
| SCHEMBL25400695 | 0.82 | HSP90AA1 (0.43) | TYMPTK2LMNA | |
| SCHEMBL7708532 | 0.82 | TYMP (0.46) | TYMPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | TYMP 4/4885TK2 77/4885RNASE1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.